Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

B Smith, F Medda, V Gokhale… - ACS chemical …, 2012 - ACS Publications
With 24.3 million people affected in 2005 and an estimated rise to 42.3 million in 2020,
dementia is currently a leading unmet medical need and costly burden on public health …
被引用次数：152 相关文章

[引用][C] Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of …

B Smith, F Medda, V Gokhale, T Dunckley… - ACS Chemical …, 2012 - cir.nii.ac.jp
Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A
Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s? | CiNii Research …

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

B Smith, F Medda, V Gokhale, T Dunckley… - ACS Chemical …, 2012 - europepmc.org
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A
inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? - Abstract - Europe …

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: A new avenue for a disease modifying treatment of Alzheimers?

B Smith, F Medda, V Gokhale… - ACS chemical …, 2012 - asu.elsevierpure.com
With 24.3 million people affected in 2005 and an estimated rise to 42.3 million in 2020,
dementia is currently a leading unmet medical need and costly burden on public health …
[HTML] nih.gov

[HTML][HTML] Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of …

B Smith, F Medda, V Gokhale, T Dunckley… - ACS Chemical …, 2012 - ncbi.nlm.nih.gov
Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A
Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s? - PMC Back to …

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

B Smith, F Medda, V Gokhale… - ACS chemical …, 2012 - pubmed.ncbi.nlm.nih.gov
With 24.3 million people affected in 2005 and an estimated rise to 42.3 million in 2020,
dementia is currently a leading unmet medical need and costly burden on public health …

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

B Smith, F Medda, V Gokhale, T Dunckley… - ACS Chemical …, 2012 - europepmc.org
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A
inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? - Abstract - Europe …